Excision BioTherapeutics has licensed recently discovered CRISPR gene editors from UC Berkeley. The deal gives Excision the exclusive right to use the Cas9 alternatives to treat infectious diseases.
SAN FRANCISCO, May 13, 2024 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc. (“Excision”, the “Company”), a clinical-stage biotechnology company developing CRISPR-based therapies to cure latent ...
A CRISPR-Cas9 gene editing technology that has shown promise in clearing HIV from mice is headed into human testing. Excision BioTherapeutics will usher the CRISPR-based therapy EBT-101 into clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results